A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A

Inclusion Criteria

• •Male, aged 12 to 65 years
• •Severe hemophilia A
• •History of more than 150 exposure days (ED) with clotting factor concentrates
• •Currently receiving episodic treatment with FVIII; no regular prophylaxis for more than 6 consecutive months in the past 5 years
• •No current Factor VIII inhibitor or history of inhibitor
• •Willing to use electronic patient diary